<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29262841</article-id><article-id pub-id-type="pmc">5738041</article-id><article-id pub-id-type="publisher-id">2341</article-id><article-id pub-id-type="doi">10.1186/s13063-017-2341-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Update</subject></subj-group></article-categories><title-group><article-title>Statistical analysis plan for the ‘Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage’ (TICH-2) trial</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8728-2199</contrib-id><name><surname>Flaherty</surname><given-names>Katie</given-names></name><address><email>katie.flaherty@nottingham.ac.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bath</surname><given-names>Philip M.</given-names></name><address><email>philip.bath@nottingham.ac.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Dineen</surname><given-names>Robert</given-names></name><address><email>rob.dineen@nottingham.ac.uk</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Law</surname><given-names>Zhe</given-names></name><address><email>zhe.law@nottingham.ac.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Scutt</surname><given-names>Polly</given-names></name><address><email>polly.scutt@nottingham.ac.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pocock</surname><given-names>Stuart</given-names></name><address><email>Stuart.Pocock@lshtm.ac.uk</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Sprigg</surname><given-names>Nikola</given-names></name><address><email>nikola.sprigg@nottingham.ac.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><collab>on behalf of the TICH-2 investigators</collab></contrib><aff id="Aff1"><label>1</label>Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, City Hospital Campus, Hucknall Road, Nottingham, NG5 1PB UK </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8868</institution-id><institution-id institution-id-type="GRID">grid.4563.4</institution-id><institution>Imaging Sciences, Division of Clinical Neuroscience, </institution><institution>University of Nottingham, </institution></institution-wrap>Nottingham, UK </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0425 469X</institution-id><institution-id institution-id-type="GRID">grid.8991.9</institution-id><institution>Department of Medical Statistics, </institution><institution>London School of Hygiene and Tropical Medicine, </institution></institution-wrap>London, UK </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 1557</institution-id><institution-id institution-id-type="GRID">grid.412113.4</institution-id><institution>Department of Medicine, </institution><institution>National University of Malaysia, </institution></institution-wrap>Kuala Lumpur, Malaysia </aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>12</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>12</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>18</volume><elocation-id>607</elocation-id><history><date date-type="received"><day>2</day><month>5</month><year>2017</year></date><date date-type="accepted"><day>9</day><month>11</month><year>2017</year></date></history><permissions><copyright-statement>© The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title><offsets xml_i="5529" xml_f="5538" txt_i="11" txt_f="20">Rationale</offsets></title><p id="Par1"><offsets xml_i="5559" xml_f="6057" txt_i="21" txt_f="519">Aside from blood pressure lowering, treatment options for intracerebral haemorrhage remain limited and a proportion of patients will undergo early haematoma expansion with resultant significant morbidity and mortality. Tranexamic acid (TXA), an anti-fibrinolytic drug, has been shown to significantly reduce mortality in patients, who are bleeding following trauma, when given rapidly. TICH-2 is testing whether TXA is effective at improving outcome in spontaneous intracerebral haemorrhage (SICH).</offsets></p></sec><sec><title><offsets xml_i="6079" xml_f="6097" txt_i="521" txt_f="539">Methods and design</offsets></title><p id="Par2"><offsets xml_i="6118" xml_f="6499" txt_i="540" txt_f="921">TICH-2 is a pragmatic, phase III, prospective, double-blind, randomised placebo-controlled trial. Two thousand adult (aged ≥ 18 years) patients with an acute SICH, within 8 h of stroke onset, will be randomised to receive TXA or the placebo control. The primary outcome is ordinal shift of modified Rankin Scale score at day 90. Analyses will be performed using intention-to-treat.</offsets></p></sec><sec><title><offsets xml_i="6521" xml_f="6528" txt_i="923" txt_f="930">Results</offsets></title><p id="Par3"><offsets xml_i="6549" xml_f="6993" txt_i="931" txt_f="1375">This paper and its attached appendices describe the statistical analysis plan (SAP) for the trial and were developed and published prior to database lock and unblinding to treatment allocation. The SAP includes details of analyses to be undertaken and unpopulated tables which will be reported in the primary and key secondary publications. The database will be locked in early 2018, ready for publication of the results later in the same year.</offsets></p></sec><sec><title><offsets xml_i="7015" xml_f="7025" txt_i="1377" txt_f="1387">Discussion</offsets></title><p id="Par4"><offsets xml_i="7046" xml_f="7270" txt_i="1388" txt_f="1612">The SAP details the analyses that will be done to avoid bias arising from prior knowledge of the study findings. The trial will determine whether TXA can improve outcome after SICH, which currently has no definitive therapy.</offsets></p></sec><sec><title><offsets xml_i="7292" xml_f="7310" txt_i="1614" txt_f="1632">Trial registration</offsets></title><p id="Par5"><offsets xml_i="7331" xml_f="7352" txt_i="1633" txt_f="1654">ISRCTN registry, ID: </offsets><ext-link ext-link-type="uri" xlink:href="http://www.isrctn.com/ISRCTN93732214"><offsets xml_i="7432" xml_f="7446" txt_i="1654" txt_f="1668">ISRCTN93732214</offsets></ext-link><offsets xml_i="7457" xml_f="7489" txt_i="1668" txt_f="1700">. Registered on 17 January 2013.</offsets></p></sec><sec><title><offsets xml_i="7511" xml_f="7544" txt_i="1702" txt_f="1735">Electronic supplementary material</offsets></title><p><offsets xml_i="7555" xml_f="7694" txt_i="1736" txt_f="1875">The online version of this article (doi:10.1186/s13063-017-2341-5) contains supplementary material, which is available to authorized users.</offsets></p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Hyperacute</kwd><kwd>Spontaneous intracerebral haemorrhage</kwd><kwd>Tranexamic acid</kwd><kwd>Randomised trial</kwd><kwd>Placebo-controlled</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000664</institution-id><institution>Health Technology Assessment Programme</institution></institution-wrap></funding-source><award-id>11_129_109</award-id><principal-award-recipient><name><surname>Sprigg</surname><given-names>Nikola</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title><offsets xml_i="8588" xml_f="8598" txt_i="1884" txt_f="1894">Background</offsets></title><p id="Par35"><offsets xml_i="8620" xml_f="9183" txt_i="1895" txt_f="2458">Haemorrhagic stroke or intracerebral haemorrhage (ICH), caused by bleeding in the brain, can be devastating and is a common cause of death and disability, both in the UK and worldwide. Despite development of effective treatments for ischaemic stroke (thrombolysis, aspirin, hemicraniectomy, thrombectomy) there is no proven effective treatment for ICH. Outcome after ICH is closely related to whether brain bleeding expands after onset, so-called haematoma expansion, or whether re-bleeding occurs; both are associated with a poor outcome (death and disability) [</offsets><xref ref-type="bibr" rid="CR1"><offsets xml_i="9215" xml_f="9216" txt_i="2458" txt_f="2459">1</offsets></xref><offsets xml_i="9223" xml_f="9757" txt_i="2459" txt_f="2993">]. Haematoma expansion is related to both haemostatic factors and blood pressure; furthermore, haematoma volume can be reduced surgically. For ICH, aside from intensive blood pressure lowering, treatment options remain limited and a proportion of patients will undergo early haematoma expansion with resultant significant morbidity and mortality. An ICH that occurs in the absence of a known underlying cause, e.g. aneurysm, arteriovenous malformation (AVM) or tumour, is referred to as a spontaneous intracerebral haemorrhage (SICH).</offsets></p><p id="Par36"><offsets xml_i="9775" xml_f="9950" txt_i="2994" txt_f="3169">Tranexamic acid (TXA) is a licensed anti-fibrinolytic drug that can be administered intravenously or orally and is used in a number of bleeding conditions to reduce bleeding [</offsets><xref ref-type="bibr" rid="CR2"><offsets xml_i="9982" xml_f="9983" txt_i="3169" txt_f="3170">2</offsets></xref><offsets xml_i="9990" xml_f="9992" txt_i="3170" txt_f="3172">, </offsets><xref ref-type="bibr" rid="CR3"><offsets xml_i="10024" xml_f="10025" txt_i="3172" txt_f="3173">3</offsets></xref><offsets xml_i="10032" xml_f="10191" txt_i="3173" txt_f="3332">]. It has been tested in aneurysmal subarachnoid haemorrhage, where it reduced the risk of re-bleeding at the expense of increased risk of cerebral ischaemia [</offsets><xref ref-type="bibr" rid="CR4"><offsets xml_i="10223" xml_f="10224" txt_i="3332" txt_f="3333">4</offsets></xref><offsets xml_i="10231" xml_f="10543" txt_i="3333" txt_f="3645">]; however, administration was for a week, conferring prolonged exposure to risk of ischaemic events. In a recent mega-trial (CRASH-2) in 20,000 patients, with major bleeding following trauma, TXA significantly reduced mortality, odds ratio (OR) 0.91 (0.85, 0.97), with no increase in vascular occlusive events [</offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="10575" xml_f="10576" txt_i="3645" txt_f="3646">5</offsets></xref><offsets xml_i="10583" xml_f="10715" txt_i="3646" txt_f="3778">]. Treatment was most effective when given rapidly; delayed administration was associated with lack of efficacy and potential harm [</offsets><xref ref-type="bibr" rid="CR6"><offsets xml_i="10747" xml_f="10748" txt_i="3778" txt_f="3779">6</offsets></xref><offsets xml_i="10755" xml_f="10966" txt_i="3779" txt_f="3990">]. In another randomised controlled trial in traumatic ICH, TXA showed trends towards reduced death: OR 0.69 (0.35, 1.39), and death or dependency: OR 0.76 (0.46, 1.27), without increased thromboembolic events [</offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="10998" xml_f="10999" txt_i="3990" txt_f="3991">7</offsets></xref><offsets xml_i="11006" xml_f="11161" txt_i="3991" txt_f="4146">]. Additionally, TXA has been found to restrict haematoma expansion in acute SICH in a small non-randomised study, although this did not report on safety [</offsets><xref ref-type="bibr" rid="CR8"><offsets xml_i="11193" xml_f="11194" txt_i="4146" txt_f="4147">8</offsets></xref><offsets xml_i="11201" xml_f="11228" txt_i="4147" txt_f="4174">]. In another small study (</offsets><italic><offsets xml_i="11236" xml_f="11237" txt_i="4174" txt_f="4175">n</offsets></italic><offsets xml_i="11246" xml_f="11377" txt_i="4175" txt_f="4306"> = 156), rapid administration of a bolus of TXA within 24 h of stroke was observed to reduce haematoma expansion (17.5% vs. 4.3%) [</offsets><xref ref-type="bibr" rid="CR9"><offsets xml_i="11409" xml_f="11410" txt_i="4306" txt_f="4307">9</offsets></xref><offsets xml_i="11417" xml_f="11706" txt_i="4307" txt_f="4596">]. In this study, TXA was given in combination with intensive blood pressure control, suggesting that it may be possible to combine haemostatic and haemodynamic approaches. There have been recent calls in the academic literature for large clinical trials to examine the use of TXA in ICH [</offsets><xref ref-type="bibr" rid="CR10"><offsets xml_i="11739" xml_f="11741" txt_i="4596" txt_f="4598">10</offsets></xref><offsets xml_i="11748" xml_f="11750" txt_i="4598" txt_f="4600">].</offsets></p><p id="Par37"><offsets xml_i="11768" xml_f="12226" txt_i="4601" txt_f="5056">The on-going TICH-2 trial is a phase III, prospective, double-blind, randomised placebo-controlled trial, which will assess whether TXA (intravenous 1 g bolus, 1 g infusion/8 h) in acute (&lt;8 h) SICH is safe and reduces death or dependency (measured as a shift in the modified Rankin Scale (mRS) score). TICH-2 is pragmatic in design, with minimal inclusion and exclusion criteria. Further information regarding randomisation can be found in the protocol [</offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="12259" xml_f="12261" txt_i="5056" txt_f="5058">11</offsets></xref><offsets xml_i="12268" xml_f="13326" txt_i="5058" txt_f="6116">]. TICH-2 followed a two-phase design: the 12-month start-up phase (to assess feasibility) aimed to recruit a minimum of 300 participants from 30 centres, then the main phase is continuing to recruit to a target of 2000 participants from 120 centres over 43 months. The Independent Data Monitoring Committee (iDMC) assessed the trial every 6 months and recommended that the trial should continue on each occasion. Whilst recruitment in the UK was ahead of schedule, recruitment internationally was delayed by prolonged approval processes. Therefore, a 12-month, no-cost extension was sought and approved in April 2016 to allow additional time to enable the trial to reach 2000 participants. Recruitment rate subsequently increased, with recruitment likely to exceed the original 2000 participant target. The Trial Steering Committee recommended that recruitment continues until the end of the allotted funding in order to maximise recruitment, international participants, recruitment into the magnetic resonance imaging (MRI) sub-study and statistical power.</offsets></p></sec><sec id="Sec2"><title><offsets xml_i="13358" xml_f="13376" txt_i="6118" txt_f="6136">Methods and design</offsets></title><p id="Par38"><offsets xml_i="13398" xml_f="13463" txt_i="6137" txt_f="6202">The statistical analysis plan (SAP), detailed in Additional file </offsets><xref rid="MOESM1" ref-type="media"><offsets xml_i="13499" xml_f="13500" txt_i="6202" txt_f="6203">1</offsets></xref><offsets xml_i="13507" xml_f="13717" txt_i="6203" txt_f="6413">, will ensure that the analyses are not data driven or selectively reported. Presentation of primary analyses is expected in spring 2018, after all participants have been followed up to day 90. Additional file </offsets><xref rid="MOESM1" ref-type="media"><offsets xml_i="13753" xml_f="13754" txt_i="6413" txt_f="6414">1</offsets></xref><offsets xml_i="13761" xml_f="13884" txt_i="6414" txt_f="6537"> will detail tables to be included in the primary publication, as well as brief descriptions of other planned publications.</offsets></p><p id="Par39"><offsets xml_i="13902" xml_f="14446" txt_i="6538" txt_f="7082">The primary outcome, death or dependency (ordinal shift on mRS) at day 90, will be analysed by intention-to-treat using ordinal logistic regression (OLR), with adjustment for minimisation factors. Whilst there are limitations to using an ordinal analysis of the mRS score (for example, moving from a 6 to a 5 may not be perceived as clinically useful and distances between points are not always equivalent), this approach is widely accepted across stroke trials and recommended by the European Stroke Organisation (ESO) Outcomes Working Party [</offsets><xref ref-type="bibr" rid="CR12"><offsets xml_i="14479" xml_f="14481" txt_i="7082" txt_f="7084">12</offsets></xref><offsets xml_i="14488" xml_f="14662" txt_i="7084" txt_f="7258">]. A number of secondary and sub-group analyses will be undertaken; time to randomisation is likely to be the most important sub-group and so will be examined in more detail.</offsets></p><p id="Par40"><offsets xml_i="14680" xml_f="15357" txt_i="7259" txt_f="7936">The results will determine whether TXA can improve outcome after SICH, which currently has no proven therapy. Three sub-studies are being run in conjunction with the trial; one for a telephone follow-up at day 365, one which takes two MRI scans at days 5 and 90 and the third one is a single-centre sub-study that explores plasma biomarkers at baseline, day 2, and day 7. A number of secondary publications are also planned, including; a paper giving further details on randomisation and baseline characteristics and a number of papers addressing secondary outcomes. An individual patient data meta-analysis is planned; using data from studies that looked at using TXA for ICH.</offsets></p><sec id="Sec3"><title><offsets xml_i="15383" xml_f="15395" txt_i="7937" txt_f="7949">Data sharing</offsets></title><p id="Par41"><offsets xml_i="15417" xml_f="15623" txt_i="7950" txt_f="8156">Once completed, data from TICH-2 will be added to summary and individual patient data meta-analyses in acute stroke. IPD will be made available to the ‘Virtual International Stroke Trials Archive’ (VISTA) [</offsets><xref ref-type="bibr" rid="CR13"><offsets xml_i="15656" xml_f="15658" txt_i="8156" txt_f="8158">13</offsets></xref><offsets xml_i="15665" xml_f="15739" txt_i="8158" txt_f="8232">], and subsequently over the web, as with the International Stroke Trial [</offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="15772" xml_f="15774" txt_i="8232" txt_f="8234">14</offsets></xref><offsets xml_i="15781" xml_f="15869" txt_i="8234" txt_f="8322">]. Similarly, anonymised baseline and on-treatment neuroimaging data will be published [</offsets><xref ref-type="bibr" rid="CR15"><offsets xml_i="15902" xml_f="15904" txt_i="8322" txt_f="8324">15</offsets></xref><offsets xml_i="15911" xml_f="15913" txt_i="8324" txt_f="8326">].</offsets></p></sec><sec id="Sec4"><title><offsets xml_i="15945" xml_f="15967" txt_i="8328" txt_f="8350">Supporting information</offsets></title><p id="Par42"><offsets xml_i="15989" xml_f="16091" txt_i="8351" txt_f="8453">Additional supporting information may be found in the online version of this article. Additional file </offsets><xref rid="MOESM1" ref-type="media"><offsets xml_i="16127" xml_f="16128" txt_i="8453" txt_f="8454">1</offsets></xref><offsets xml_i="16135" xml_f="16159" txt_i="8454" txt_f="8478"> shows the SAP (TICH-2).</offsets></p><sec id="Sec5"><title><offsets xml_i="16185" xml_f="16197" txt_i="8479" txt_f="8491">Trial status</offsets></title><p id="Par43"><offsets xml_i="16219" xml_f="16405" txt_i="8492" txt_f="8678">At the time of first submission the TICH-2 trial was ongoing with recruitment due to finish on 30 September 2017 and with follow-up of the primary outcome ongoing until 30 December 2017.</offsets></p></sec></sec></sec></body><back><app-group><app id="App1"><sec id="Sec6"><title>Additional file</title><p id="Par50">
<media position="anchor" xlink:href="13063_2017_2341_MOESM1_ESM.docx" id="MOESM1"><label>Additional file 1:</label><caption><p>‘TICH-2 statistical analysis plan (SAP) appendix V1.6.doc’ includes: Appendix A – SAP; Appendix B – definitions; Appendix C – tables and figures; Appendix D – secondary publications. (DOCX 611 kb)</p></caption></media>
</p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>BLR</term><def><p id="Par6">Binary logistic regression</p></def></def-item><def-item><term>CPHR</term><def><p id="Par7">Cox proportional hazards regression</p></def></def-item><def-item><term>CT</term><def><p id="Par8">Computed tomography</p></def></def-item><def-item><term>EQ-5D HUS</term><def><p id="Par9">EuroQol 5-dimensions Health Utility Status</p></def></def-item><def-item><term>EQ-VAS</term><def><p id="Par10">EuroQol Visual Analogue Scale</p></def></def-item><def-item><term>GCS</term><def><p id="Par11">Glasgow coma scale</p></def></def-item><def-item><term>HE</term><def><p id="Par12">Haematoma expansion</p></def></def-item><def-item><term>HR</term><def><p id="Par13">Hazard ratio</p></def></def-item><def-item><term>HV</term><def><p id="Par14">Haematoma volume</p></def></def-item><def-item><term>ICH</term><def><p id="Par15">Intracerebral haemorrhage</p></def></def-item><def-item><term>IHD</term><def><p id="Par16">Ischaemic heart disease</p></def></def-item><def-item><term>IQR</term><def><p id="Par17">Interquartile range</p></def></def-item><def-item><term>ITT</term><def><p id="Par18">Intention-to-treat</p></def></def-item><def-item><term>IVH</term><def><p id="Par19">Intraventricular haemorrhage</p></def></def-item><def-item><term>MD</term><def><p id="Par20">Mean difference</p></def></def-item><def-item><term>MLR</term><def><p id="Par21">Multiple linear regression</p></def></def-item><def-item><term>mRS</term><def><p id="Par22">modified Rankin Scale</p></def></def-item><def-item><term>NIHSS</term><def><p id="Par23">National Institutes of Health Stroke Scale</p></def></def-item><def-item><term>OCSP</term><def><p id="Par24">Oxfordshire Community Stroke Project classification</p></def></def-item><def-item><term>OLR</term><def><p id="Par25">Ordinal logistic regression</p></def></def-item><def-item><term>OR</term><def><p id="Par26">Odds ratio</p></def></def-item><def-item><term>SAE</term><def><p id="Par27">Serious adverse event</p></def></def-item><def-item><term>SAP</term><def><p id="Par28">Statistical analysis plan</p></def></def-item><def-item><term>SBP</term><def><p id="Par29">Systolic blood pressure</p></def></def-item><def-item><term>SD</term><def><p id="Par30">Standard deviation</p></def></def-item><def-item><term>SICH</term><def><p id="Par31">Spontaneous intracerebral haemorrhage</p></def></def-item><def-item><term>TIA</term><def><p id="Par32">Transient ischaemic attack</p></def></def-item><def-item><term>TICS-M</term><def><p id="Par33">Telephone Interview for Cognitive Status-M</p></def></def-item><def-item><term>ZDS</term><def><p id="Par34">Zung Depression Scale</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (doi:10.1186/s13063-017-2341-5) contains supplementary material, which is available to authorized users.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable</p><sec id="FPar1"><title>Funding</title><p id="Par44">This project was funded by the National Institute for Health Research, Health Technology Assessment (project number 11_129_109) Pragmatic Trials, UK and Swiss Heart foundation in Switzerland. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Health Technology Assessment, NIHR, the NHS or the Department of Health.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par45">Not applicable</p></sec></ack><notes notes-type="author-contribution"><title>Authors’ contributions</title><p>KF, PS, RD, ZL, and NS had an input in drafting and finalising the statistical analysis plan. All authors read and approved the manuscript for publication. NS was the chief investigator for this trial.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par46">The study received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) on 23 October 2012, the Research Ethics Committee (REC) on 23 November 2012, and the respective National Health Service Research and Development (R&amp;D) department on 15 February 2013. Consent was obtained from all participants prior to enrolment into the trial. Ethics approval was obtained to allow full informed consent or verbal assent (using a Brief Information Sheet) followed by full written consent at a later date.</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par47">Not applicable</p></sec><sec id="FPar5"><title>Competing interests</title><p id="Par48">The authors declare that they have no competing interests.</p></sec><sec id="FPar6"><title>Publisher’s Note</title><p id="Par49">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steiner</surname><given-names>T</given-names></name><name><surname>Bösel</surname><given-names>J</given-names></name></person-group><article-title>Options to restrict hematoma expansion after spontaneous intracerebral hemorrhage</article-title><source>Stroke</source><year>2010</year><volume>41</volume><issue>2</issue><fpage>402</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.109.552919</pub-id><pub-id pub-id-type="pmid">20044536</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunn</surname><given-names>CJ</given-names></name><name><surname>Goa</surname><given-names>KL</given-names></name></person-group><article-title>Tranexamic acid</article-title><source>Drugs</source><year>1999</year><volume>57</volume><issue>6</issue><fpage>1005</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.2165/00003495-199957060-00017</pub-id><pub-id pub-id-type="pmid">10400410</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>I</given-names></name><etal></etal></person-group><article-title>Antifibrinolytic drugs for acute traumatic injury</article-title><source>Cochrane Database Syst Rev.</source><year>2011</year><volume>1</volume><fpage>CD004896</fpage></element-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Roos YB, et al. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Libr. 2013;(8):CD001245. doi: 10.1002/14651858</mixed-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams-Johnson</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2). A randomised, placebo-controlled trial</article-title><source>West Indian Med J</source><year>2010</year><volume>59</volume><issue>6</issue><fpage>612</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">21702233</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">CRASH-2 Collaborators, I.B.S. Effect of tranexamic acid in traumatic brain injury: a nested randomised, placebo controlled trial (CRASH-2 Intracranial Bleeding Study). BMJ. 2011;343. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/bmj.d3795">https://doi.org/10.1136/bmj.d3795</ext-link></mixed-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Yutthakasemsunt</surname><given-names>S</given-names></name><etal></etal></person-group><source>Tranexamic Acid for preventing progressive intracranial hemorrage in adults with traumatic brain injury; a preliminary report presented at the National Neurotrauma Symposium</source><year>2010</year></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ojacastro</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Efficacy of tranexamic acid in reducing hematoma volume in patients with hypertensive intracerebral hemorrhage</article-title><source>Int J Stroke.</source><year>2008</year><volume>3</volume><issue>Suppl 1</issue><fpage>197</fpage><lpage>8</lpage></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorimachi</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Rapid administration of antifibrinolytics and strict blood pressure control for intracerebral hemorrhage</article-title><source>Neurosurgery</source><year>2005</year><volume>57</volume><issue>5</issue><fpage>837</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1227/01.NEU.0000180815.38967.57</pub-id><pub-id pub-id-type="pmid">16284553</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Roos YB. Tranexamic acid for traumatic brain injury. BMJ. 2011;343:163–68.</mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Sprigg N, et al. Intravenous tranexamic acid for hyperacute primary intracerebral hemorrhage: protocol for a randomized, placebo-controlled trial. Int J Stroke. 2016;11(6):683–94.</mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Wilson A, Bath PMW, Berge E, Cadilhac DA, Cuche M, Ford GA, Macisaac R, Quinn TJ, Taylor M, Walters M, Wolff C, Lees KR. Understanding the relationship between costs and the modified Rankin Scale: A systematic review, multidisciplinary consensus and recommendations for future studies. Eur Stroke J. 2016;2(1):3–12.</mixed-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>The virtual international stroke trials archive (VISTA)</article-title><source>Stroke.</source><year>2007</year><volume>38</volume><fpage>1905</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.106.473579</pub-id><pub-id pub-id-type="pmid">17446430</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandercock</surname><given-names>PA</given-names></name><name><surname>Niewada</surname><given-names>M</given-names></name><name><surname>Czlonkowska</surname><given-names>A</given-names></name></person-group><article-title>The International Stroke Trial database</article-title><source>Trials</source><year>2011</year><volume>12</volume><issue>1</issue><fpage>101</fpage><pub-id pub-id-type="doi">10.1186/1745-6215-12-101</pub-id><pub-id pub-id-type="pmid">21510853</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wardlaw</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>The NeuroGrid stroke exemplar clinical trial protocol</article-title><source>Int J Stroke.</source><year>2007</year><volume>2</volume><fpage>63</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/j.1747-4949.2007.00092.x</pub-id><pub-id pub-id-type="pmid">18705995</pub-id></element-citation></ref></ref-list></back></article>